NEW YORK, March 22, 2017 /PRNewswire/ --
Stock-Callers.com has issued research reports on four Biotechnology stocks which are: Radius Health Inc. (NASDAQ: RDUS), Acorda Therapeutics Inc. (NASDAQ: ACOR), PhaseRx Inc. (NASDAQ: PZRX), and Athersys Inc. (NASDAQ: ATHX). These companies operate in the Healthcare sector, which resisted much of the steeper declines most sectors experienced on Tuesday, March 21st, 2017, with the NYSE Health Care Index falling about 0.5%, while shares of health care companies in the S&P 500 were down almost 0.6% as a group. Learn more about these stocks by downloading their free report at:
Waltham, Massachusetts headquartered Radius Health Inc.'s stock finished Tuesday's session 6.78% lower at $35.63. A total volume of 1.33 million shares was traded, which was above their three months average volume of 742,040 shares. The Company's shares are trading below their 50-day moving average by 16.78%. Furthermore, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have a Relative Strength Index (RSI) of 30.27. The free research report on RDUS is available at:
Shares in Ardsley, New York headquartered Acorda Therapeutics Inc. ended at $25.60, down 5.19% from the last trading session. The stock recorded a trading volume of 612,663 shares. The Company's shares have gained 1.19% in the last one month, 27.36% in the past three months, and 36.17% over the previous one year. The stock is trading 6.91% above its 50-day moving average and 10.72% above its 200-day moving average. Moreover, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 46.67. The complimentary report on ACOR can be downloaded at:
Seattle, Washington headquartered PhaseRx Inc.'s stock ended yesterday's session 7.01% lower at $1.46 with a total trading volume of 64,382 shares. The Company's shares have advanced 10.61% over the previous three months. The stock is trading 6.38% below its 50-day moving average. Additionally, shares of PhaseRx, which engages in developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children, have an RSI of 42.85. Visit us today and download our complete research report on PZRX for free at:
On Tuesday, shares in Cleveland, Ohio headquartered Athersys Inc. recorded a trading volume of 809,954 shares, which was above their three months average volume of 768,650 shares. The stock finished 1.75% higher at $1.16. The Company's shares are trading below their 50-day moving average by 7.51%. Furthermore, shares of Athersys, which focuses on the research and development activities in the field of regenerative medicine, have an RSI of 42.25. Get free access to your technical report on ATHX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA